Inventor · disambiguated record
Patrick Van Berkel
Also filed as: VAN BERKEL PATRICIUS HENDRIKUS CORNELIS · VAN BERKEL PATRICK · VAN BERKEL PATRICK H C · VAN BERKEL PATRICK HENDRIKUS CORNELIS
19 granted patents·21 pending applications·741 citations·filing 1998–2024
96Inventor score
Top patents by PatentIndex Score
40 records- 0198US7932360B2Recombinant production of mixtures of antibodiesMERUS B V·Filed 2006·Granted Apr 26, 2011·41 cites·17 claims
- 0298US7429486B2Recombinant production of mixtures of antibodiesCRUCELL HOLLAND BV·Filed 2006·Granted Sep 30, 2008·82 cites·20 claims
- 0398US7262028B2Recombinant production of mixtures of antibodiesCRUCELL HOLLAND BV·Filed 2005·Granted Aug 28, 2007·245 cites·20 claims
- 0497US11866514B2Heterodimeric antibody Fc-containing proteins and methods for production thereofGENMAB AS·Filed 2020·Granted Jan 9, 2024·5 cites·37 claims
- 0597US10597464B2Heterodimeric antibody Fc-containing proteins and methods for production thereofGENMAB AS·Filed 2017·Granted Mar 24, 2020·35 cites·12 claims
- 0697US9150663B2Heterodimeric antibody Fc-containing proteins and methods for production thereofLABRIJN ARAN FRANK·Filed 2011·Granted Oct 6, 2015·119 cites·37 claims
- 0797US7927834B2Recombinant production of mixtures of antibodiesMERUS B V·Filed 2008·Granted Apr 19, 2011·42 cites·23 claims
- 0895US10344050B2Production of heterodimeric proteinsGENMAB AS·Filed 2012·Granted Jul 9, 2019·40 cites·52 claims
- 0993US11492371B2Production of heterodimeric proteinsGENMAB AS·Filed 2019·Granted Nov 8, 2022·9 cites·21 claims
- 1093US9492565B2Human antibody drug conjugates against tissue factorGENMAB AS·Filed 2015·Granted Nov 15, 2016·7 cites·16 claims
- 1192US9168314B2Human antibody drug conjugates against tissue factorSATIJN DAVID·Filed 2011·Granted Oct 27, 2015·29 cites·11 claims
- 1286US2024294661A1Human antibody drug conjugates against tissue factorGENMAB AS·Filed 2023·Application pending·0 cites
- 1386US2024209117A1Heterodimeric antibody fc-containing proteins and methods for production thereofGENMAB AS·Filed 2023·Application pending·0 cites
- 1482US10351629B2Recombinant IgG4 monovalent antibodiesGENMAB AS·Filed 2016·Granted Jul 16, 2019·2 cites·24 claims
- 1582US10323081B2Modulation of complement-dependent cytotoxicity through modifications of the C-terminus of antibody heavy chainsPARREN PAUL·Filed 2012·Granted Jun 18, 2019·3 cites·6 claims
- 1682US6333311B1Useful properties of human lactoferrin and variants thereofPHARMING·Filed 1998·Granted Dec 25, 2001·67 cites·20 claims
- 1780US9540433B2Human antibodies and antibody-drug conjugates against CD74VERPLOEGEN SANDRA·Filed 2012·Granted Jan 10, 2017·6 cites·43 claims
- 1880US2025066506A1Bispecific antibodies against her2GENMAB AS·Filed 2024·Application pending·0 cites
- 1979US9322035B2Recombinant IgG4 monovalent antibodiesSCHUURMAN JANINE·Filed 2008·Granted Apr 26, 2016·2 cites·6 claims
- 2074US2021395384A1Human antibody drug conjugates against tissue factorGENMAB AS·Filed 2021·Application pending·0 cites
- 2173US10155816B2Recombinant monovalent antibodies and methods for production thereofPARREN PAUL·Filed 2006·Granted Dec 18, 2018·1 cites·17 claims
- 2273US2023227495A1Production of heterodimeric proteinsGENMAB AS·Filed 2022·Application pending·0 cites
- 2372US2022396629A1Recombinant monovalent antibodies and methods for production thereofGENMAB AS·Filed 2022·Application pending·0 cites
- 2470US7060677B1Antimicrobial activity of the first cationic cluster of human lactoferrinAM PHARMA BV·Filed 2000·Granted Jun 13, 2006·6 cites·41 claims
- 2569US2022323582A1Human antibodies and antibody-drug conjugates against cd74GENMAB AS·Filed 2021·Application pending·0 cites
- 2667US11795214B2Modulation of complement-dependent cytotoxicity through modifications of the C-terminus of antibody heavy chainsGENMAB AS·Filed 2019·Granted Oct 24, 2023·0 cites·23 claims
- 2767US2021324105A1Bispecific antibodies against her2GENMAB AS·Filed 2021·Application pending·0 cites
- 2866US2019315880A1Human antibody drug conjugates against tissue factorGENMAB AS·Filed 2019·Application pending·0 cites
- 2965US2017136130A1Human antibody drug conjugates against tissue factorGENMAB AS·Filed 2016·Application pending·0 cites
- 3065US2022177585A1Potency assays for antibody drug substance binding to an fc receptorGENMAB AS·Filed 2021·Application pending·0 cites
- 3158US2017362319A1Potency assays for antibody drug substance binding to an fc receptorGENMAB AS·Filed 2017·Application pending·0 cites
- 3257US2019169298A1Recombinant monovalent antibodies and methods for production thereofGENMAB AS·Filed 2018·Application pending·0 cites
- 3355US2016046727A1Heterodimeric antibody fc-containing proteins and methods for production thereofGENMAB AS·Filed 2015·Application pending·0 cites
- 3453US2017369590A1Bispecific antibodies against her2GENMAB AS·Filed 2017·Application pending·0 cites
- 3551US2010255012A1Recombinant fucose modified monovalent half-antibodies obtained by molecular engineeringGENMAB AS·Filed 2008·Application pending·0 cites
- 3650US2022111065A1Molecular adjuvantADC THERAPEUTICS SA·Filed 2019·Application pending·0 cites
- 3749US2010325744A1Non-glycosylated recombinant monovalent antibodiesGENMAB AS·Filed 2008·Application pending·0 cites
- 3849US2011045007A1Fusion or linked proteins with extended half lifeGENMAB AS·Filed 2008·Application pending·0 cites
- 3949US2017173151A1Human antibodies and antibody-drug conjugates against cd74GENMAB AS·Filed 2016·Application pending·0 cites
- 4041US2014170148A1Bispecific antibodies against her2DE GOEIJ BART·Filed 2012·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →